Ironwood slips as heartburn data underwhelm investors A phase 2b trial of Ironwood Pharmaceuticals’ IW-3718 has met its primary endpoint, teeing the heartburn candidate up to move into a pivotal […]
Despite scoring an FDA nod, Merck’s biosim Lusduna must wait to challenge Lantus Sanofi’s top-selling Lantus is already contending with one copycat rival, and Merck & Co. just won FDA […]
Discount helps NICE flip-flop on Teva’s severe asthma contender, Cinqair There’s still no word on whether Teva has landed AstraZeneca CEO Pascal Soriot or if he is staying put, as […]
Attacking muscle diseases like ALS by clearing protein clumps Researchers have identified a process that promotes the protein clumping characteristic of degenerative diseases. While the work is in early stages, […]
Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble? Gilead is out with a brand-new second-line hepatitis C treatment—but the length of its dosing […]